Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on the Senate Finance Committee hearing: “Prescription Drug Affordability and Innovation: Addressing Challenges in Today’s Market: “We share the Administration’s goal of reducing drug prices.”
Featured
Industry News ASRAZENECA PHARMACEUTICALS LP: AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease
Federal Issues UNITEDHEALTH GROUP: UnitedHealth Group Statement on Trump Administration’s Drug Policy Proposal
Latest News
REGENERON PHARMACEUTICALS, INC.: FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
Federal Issues
- U.S. DEPARTMENT OF HOMELAND SECURITY: DHS Statement on Protecting the Nation from Foreign Terrorist Entry to the United States
- PHARMACEUTICAL CARE MANAGEMENT CARE ASSOCIATION: Federal Circuit Court Unanimously Strikes Down Arkansas Mandate Restricting PBM Tools
- PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION: Congressional Budget Office Score of Medicare Point-of-Sale Rebates Undermines Drugmakers’ Signature Issue
- U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES: HHS Secretary Azar Praises FDA Approval of First Non-Opioid Treatment for Opioid Withdrawal
Industry News
ASTELLAS PHARMA US, INC: Astellas Statement on U.S. Drug Pricing
- UPPER-SMITH LABORATORIES, INC: UPSHER-SMITH EXPANDS PORTFOLIO WITH SIXTH PRODUCT LAUNCH IN 2018
- TEVA PHARMACEUTICALS USA, INC: Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United States
- ACADIA PHARMACEUTICALS INC.: ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome
- PORTOLA PHARMACEUTICALS: U.S. Centers for Medicare and Medicaid Services (CMS) Grants New Technology Add-On Payment for Portola Pharmaceuticals’ Andexxa
Innovation
- SANOFI US: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
- BAXTER: Baxter Announces U.S. FDA Clearance of New Spectrum IQ Infusion System
- ELI LILLY AND COMPANY: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
- GILEAD SCIENCES, INC: U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
Regulatory
RITE AID: Establishes Policy for Addressing Chemicals of Consumer Concern
- U.S. FOOD AND DRUG ASSOCIATION (FDA): Announces voluntary recall of Montelukast tablets by Camber Pharmaceuticals due to incorrect drug in bottles
- BRISTOL-MYERS SQUIBB: European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection
- PFIZER: U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
- GENENTECH, INC: Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy
Alerts Sign-up